Clinical Trial Update: A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma [Phase 3]

View source ↗

Summary

This document reports on a completed randomized Phase III trial evaluating hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and inter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Interferon-gamma (interferon gamma)
• Melphalan (Melphalan)
• tumor necrosis factor-alpha (tumor necrosis factor-alpha)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma | Phase 3 | Status: COMPLETED